Triple-negative breast cancer (TNBC), lacking the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2), accounts for about 10–15% and is the most aggressive molecular subtype of all breast tumors (Sung et al., 2021; Wang et al., 2021). Here, ERBB2 is linked to breast neoplasm.